Wstęp
Ta strona zawiera kompleksową analizę znanej historii wykorzystywania informacji poufnych w firmie Fred A Middleton. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Dokonywanie transakcji w ich firmach w oparciu o określone, niepubliczne informacje jest nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4. Pomimo tych ograniczeń badania akademickie sugerują, że insiderzy – ogólnie rzecz biorąc – mają tendencję do osiągania lepszych wyników na rynku w swoich własnych firmach.
Średnia rentowność handlu
Średnia rentowność handlu to średni zwrot ze wszystkich zakupów na otwartym rynku dokonanych przez osobę mającą dostęp do informacji poufnych w ciągu ostatnich trzech lat. Aby to obliczyć, badamy każdy nieplanowany zakup na otwartym rynku dokonany przez insidera, z wyłączeniem wszystkich transakcji oznaczonych jako część planu handlowego 10b5-1. Następnie obliczamy średnią wydajność tych transakcji w ciągu 3, 6 i 12 miesięcy, uśredniając każdy z tych okresów, aby wygenerować ostateczny wskaźnik wydajności dla każdej transakcji. Na koniec uśredniamy wszystkie wskaźniki wydajności, aby obliczyć wskaźnik wydajności dla insidera. Na tej liście znajdują się wyłącznie insiderzy, którzy dokonali co najmniej trzech transakcji w ciągu ostatnich dwóch lat.
Jeśli rentowność handlu insiderów jest oznaczona notką„nie dotyczy”, oznacza to, że insider albo nie dokonał żadnych zakupów na otwartym rynku w ciągu ostatnich trzech lat, albo transakcje, których dokonał, są zbyt nowe, aby obliczyć wiarygodny wskaźnik wydajności.
Częstotliwość aktualizacji: codziennie
Spółki posiadające zgłoszone stanowiska osób mających dostęp do poufnych informacji
Z dokumentów SEC wynika, że Fred A Middleton zgłosił udziały lub transakcje w następujących spółkach:
| Papier wartościowy | Nazwa | Najnowsze raporty dotyczące udziałów |
|---|---|---|
| US:CMRX / Chimerix, Inc. | Director | 0 |
| US:CALC / CalciMedica, Inc. | Director, 10% Owner | 36 514 |
| US:ECYT / Endocyte, Inc. | Director | 0 |
| US:STXS / Stereotaxis, Inc. | Director | 0 |
| US:PCRX / Pacira BioSciences, Inc. | Director | 0 |
Jak interpretować wykresy
Poniższe wykresy przedstawiają notowania akcji papierów wartościowych po każdej niezaplanowanej transakcji na otwartym rynku dokonanej przez Fred A Middleton. Nieplanowane transakcje to transakcje, które nie zostały dokonane w ramach planu handlowego 10b5-1. Notowania akcji przedstawiono na wykresie jako skumulowaną procentową zmianę ceny akcji. Na przykład, jeśli 1 stycznia 2019 r. dokonano transakcji poufnej, wykres pokaże dzienną procentową zmianę papieru wartościowego do dnia dzisiejszego. Jeżeli cena akcji wzrosłaby w tym czasie z 10 do 15 dolarów, skumulowana procentowa zmiana ceny akcji wyniosłaby 50%. Zmiana ceny z 10$ na 20$ będzie wynosić 100%, a zmiana ceny z 10$ na 5$ będzie wynosić -50%.
Ostatecznie staramy się określić, jak blisko transakcje insiderów korelują z nadmiernymi zwrotami (dodatnimi lub ujemnymi) z ceny akcji, aby sprawdzić, czy insider dostosowuje swoje transakcje w taki sposób, aby czerpać korzyści z informacji poufnych. Rozważmy sytuację, w której zrobił to ktoś z wewnątrz. W tej sytuacji oczekiwalibyśmy albo (a) dodatnich zwrotów po zakupach, albo (b) ujemnych zwrotów po sprzedaży. W przypadku (a) wykres ZAKUPU pokazywałby serię krzywych nachylonych w górę, wskazujących dodatnie zwroty po każdej transakcji zakupu. W przypadku (b) wykres SPRZEDAŻ pokazywałby serię krzywych o nachyleniu w dół, wskazujących ujemne zwroty po każdej transakcji sprzedaży.
Samo to jednak nie wystarczy, aby wyciągnąć wnioski. Gdyby np. cena akcji spółki przez wiele lat rosła niecyklicznie, to spodziewalibyśmy się, że wszystkie wykresy po zakupie będą wykazywały tendencję wzrostową. Podobnie niecykliczne spadki na przestrzeni wielu lat spowodowałyby spadek linii na wykresie po transakcjach. Żaden z tych wykresów nie sugeruje wykorzystywania informacji poufnych.
Najsilniejszym wskaźnikiem byłaby sytuacja, gdy cena akcji miała charakter wyjątkowo cykliczny, a na wykresie KUPNO występowały zarówno pozytywne sygnały na wykresie KUPNA, jak i negatywne na wykresie SPRZEDAŻY. Sytuacja ta wysoce sugerowałaby osobę mającą dostęp do informacji poufnych, która wykorzystywała transakcje w celu uzyskania korzyści finansowej.
Zakupy insidera CALC / CalciMedica, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w CALC / CalciMedica, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera CALC / CalciMedica, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w CALC / CalciMedica, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do min |
Cena min |
Uniknięta maksymalna strata ($) |
Uniknięta Maksymalna strata (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera PCRX / Pacira BioSciences, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w CALC / CalciMedica, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
| Data transakcji | Ticker | Insider | Zgłoszone Akcje |
Zgłoszona Cena |
Skorygowane Akcje |
Skorygowana Cena |
Podstawa kalkulacji kosztów | Dni do maks |
Cena maks |
Maks Zysk ($) |
Maksymalny zwrot (%) |
|---|---|---|---|---|---|---|---|
| Nie znane są żadne nieplanowane transakcje na otwarttm rynku dla tej kombinacji insidera i papieru wartościowego |
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera PCRX / Pacira BioSciences, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w CALC / CalciMedica, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Zakupy insidera STXS / Stereotaxis, Inc. – krótkoterminowa analiza zysków
W tej części analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w CALC / CalciMedica, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Sprzedaż insidera STXS / Stereotaxis, Inc. — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży poufnych informacji na otwartym rynku dokonanej w CALC / CalciMedica, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji, a wyniki mają charakter teoretyczny .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Historia handlu insiderów
Ta tabela przedstawia pełną listę transakcji insiderów dokonanych przez firmę Fred A Middleton ujawnioną Komisji Papierów Wartościowych (SEC).
| Data pliku | Data trans | Formularz | Ticker | Bezpieczeństwo | Kod | Akcje | Pozostałe akcje | Zmiana procent |
Cena udziału |
Wartość trans |
Pozostała Wartość |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-21 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
D - Sale to Issuer | -207 523 | 0 | -100,00 | 8,55 | -1 774 322 | ||
| 2025-04-21 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
D - Sale to Issuer | -531 861 | 0 | -100,00 | 8,55 | -4 547 412 | ||
| 2025-04-21 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
D - Sale to Issuer | -2 776 093 | 0 | -100,00 | 8,55 | -23 735 595 | ||
| 2025-04-21 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
D - Sale to Issuer | -60 000 | 0 | -100,00 | 8,55 | -513 000 | ||
| 2025-04-21 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
D - Sale to Issuer | -40 000 | 0 | -100,00 | 8,55 | -342 000 | ||
| 2024-12-06 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 4 800 | 36 514 | 15,14 | 2,65 | 12 720 | 96 762 | |
| 2024-11-05 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 877 | 22 479 | 4,06 | 3,75 | 3 289 | 84 296 | |
| 2024-11-05 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 86 867 | 814 300 | 11,94 | 3,75 | 325 751 | 3 053 625 | |
| 2024-11-05 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 20 000 | 31 714 | 170,74 | 3,75 | 75 000 | 118 928 | |
| 2024-10-30 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
G - Gift | -60 000 | 40 000 | -60,00 | ||||
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 28 744 | 30 292 | 1 856,85 | 3,70 | 106 410 | 112 141 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 3 920 | 21 602 | 22,17 | 3,70 | 14 512 | 79 971 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 13 184 | 27 609 | 91,40 | 3,70 | 48 807 | 102 209 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 51 032 | 114 260 | 80,71 | 3,70 | 188 920 | 422 991 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 194 472 | 435 148 | 80,80 | 3,70 | 719 935 | 1 610 918 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 144 676 | 727 433 | 24,83 | 3,70 | 535 591 | 2 692 957 | |
| 2024-01-25 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 243 356 | 946 744 | 34,60 | 3,70 | 900 904 | 3 504 846 | |
| 2023-11-20 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 17 295 | 100 000 | 20,91 | 0,96 | 16 522 | 95 530 | |
| 2023-11-13 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 2 705 | 82 705 | 3,38 | 0,92 | 2 489 | 76 089 | |
| 2023-09-26 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 20 000 | 80 000 | 33,33 | 0,98 | 19 636 | 78 544 | |
| 2023-06-09 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 714 | 11 714 | 6,49 | 5,20 | 3 713 | 60 913 | |
| 2023-06-08 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 500 | 11 000 | 4,76 | 5,20 | 2 600 | 57 200 | |
| 2023-06-08 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 500 | 10 500 | 5,00 | 4,88 | 2 440 | 51 248 | |
| 2023-05-22 |
|
4 | CALC |
CalciMedica, Inc.
Common Stock |
P - Purchase | 10 000 | 10 000 | 2,85 | 28 500 | 28 500 | ||
| 2023-03-29 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 20 000 | 60 000 | 50,00 | 1,21 | 24 152 | 72 456 | |
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 8 176 | 8 176 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 1 548 | 1 548 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 47 052 | 47 052 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 14 425 | 14 425 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 256 852 | 256 852 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 8 884 | 8 884 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 7 456 | 7 456 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 17 682 | 17 682 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 582 757 | 582 757 | |||||
| 2023-03-22 |
|
4 | CALC |
CalciMedica, Inc. /DE/
Common Stock |
A - Award | 703 388 | 703 388 | |||||
| 2022-10-03 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 20 000 | 40 000 | 100,00 | 1,86 | 37 176 | 74 352 | |
| 2022-05-20 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 20 000 | 20 000 | 2,04 | 40 738 | 40 738 | ||
| 2021-06-29 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 6 950 | 207 523 | 3,47 | 7,83 | 54 418 | 1 624 905 | |
| 2021-06-29 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 3 050 | 200 573 | 1,54 | 7,78 | 23 729 | 1 560 458 | |
| 2021-06-25 |
|
4 | CMRX |
CHIMERIX INC
Stock Option (Right to Buy) |
A - Award | 35 000 | 35 000 | |||||
| 2020-06-15 |
|
4 | CMRX |
CHIMERIX INC
Stock Option (Right to Buy) |
A - Award | 35 000 | 35 000 | |||||
| 2020-03-16 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 50 000 | 197 523 | 33,89 | 1,40 | 69 900 | 276 137 | |
| 2019-11-13 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 30 000 | 147 523 | 25,53 | 1,82 | 54 567 | 268 330 | |
| 2019-11-13 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 20 000 | 117 523 | 20,51 | 1,66 | 33 190 | 195 029 | |
| 2019-06-24 |
|
4 | CMRX |
CHIMERIX INC
Stock Option (Right to Buy) |
A - Award | 21 000 | 21 000 | |||||
| 2019-05-13 |
|
4 | CMRX |
CHIMERIX INC
Common Stock |
P - Purchase | 30 000 | 97 523 | 44,43 | 2,92 | 87 678 | 285 021 | |
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -19 500 | 0 | -100,00 | 13,19 | -257 205 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -19 500 | 0 | -100,00 | 21,73 | -423 735 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -13 500 | 0 | -100,00 | 20,65 | -278 775 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -13 500 | 0 | -100,00 | 17,98 | -242 730 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -14 000 | 0 | -100,00 | 17,31 | -242 340 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -14 000 | 0 | -100,00 | 11,06 | -154 840 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -10 000 | 0 | -100,00 | 17,57 | -175 700 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -10 000 | 0 | -100,00 | 12,20 | -122 000 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
D - Sale to Issuer | -15 706 | 0 | -100,00 | 18,00 | -282 708 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -904 465 | 0 | -100,00 | 24,00 | -21 707 160 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -8 434 | 0 | -100,00 | 24,00 | -202 416 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -10 049 | 0 | -100,00 | 24,00 | -241 176 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -100 828 | 0 | -100,00 | 24,00 | -2 419 872 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -113 315 | 0 | -100,00 | 24,00 | -2 719 560 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -162 170 | 0 | -100,00 | 24,00 | -3 892 080 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -249 148 | 0 | -100,00 | 24,00 | -5 979 552 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -267 491 | 0 | -100,00 | 24,00 | -6 419 784 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -1 212 413 | 0 | -100,00 | 24,00 | -29 097 912 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -1 017 304 | 0 | -100,00 | 24,00 | -24 415 296 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -3 300 | 0 | -100,00 | 24,00 | -79 200 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
D - Sale to Issuer | -110 189 | 0 | -100,00 | 24,00 | -2 644 536 | ||
| 2018-12-21 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
G - Gift | -83 860 | 113 489 | -42,49 | ||||
| 2018-06-21 |
|
4 | CMRX |
CHIMERIX INC
Stock Option (Right to Buy) |
A - Award | 21 000 | 21 000 | |||||
| 2018-05-04 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 19 500 | 19 500 | |||||
| 2018-05-04 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 3 300 | 197 349 | 1,70 | ||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
6 155 016 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 910 784 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 382 369 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 446 446 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
6 155 016 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 910 784 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 382 369 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 446 446 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
6 155 016 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 910 784 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 382 369 | ||||||||
| 2018-04-06 | 3 | CMRX |
CHIMERIX INC
Common Stock |
3 446 446 | ||||||||
| 2018-03-30 |
|
4 | CMRX |
CHIMERIX INC
Stock Option (Right to Buy) |
A - Award | 42 000 | 42 000 | |||||
| 2018-03-05 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -153 846 | 0 | -100,00 | ||||
| 2018-03-05 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 153 846 | 303 528 | 102,78 | 0,28 | 43 077 | 84 988 | |
| 2018-03-05 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
A - Award | 153 846 | 153 846 | |||||
| 2018-03-05 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
D - Sale to Issuer | -153 846 | 0 | -100,00 | ||||
| 2018-03-01 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 119 048 | 904 465 | 15,16 | 4,20 | 500 002 | 3 798 753 | |
| 2018-03-01 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 380 952 | 1 212 413 | 45,82 | 4,20 | 1 599 998 | 5 092 135 | |
| 2018-01-02 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 30 000 | 149 682 | 25,07 | ||||
| 2017-07-06 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 30 000 | 119 682 | 33,45 | ||||
| 2017-05-05 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 19 500 | 19 500 | |||||
| 2017-05-05 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 3 300 | 194 049 | 1,73 | ||||
| 2016-10-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 153 846 | 153 846 | |||||
| 2016-10-03 |
|
4 | STXS |
Stereotaxis, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 100 | 100 | 1 000,00 | 100 000 | 100 000 | ||
| 2016-05-25 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 10 000 | 56 810 | 21,36 | ||||
| 2016-05-06 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 13 500 | 13 500 | |||||
| 2016-05-06 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 2 250 | 203 249 | 1,12 | ||||
| 2016-01-20 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
P - Purchase | 10 000 | 200 999 | 5,24 | 2,79 | 27 900 | 560 787 | |
| 2016-01-20 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
P - Purchase | 20 000 | 190 999 | 11,70 | 2,80 | 56 000 | 534 797 | |
| 2015-06-16 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -26 064 | 1 107 189 | -2,30 | 1,57 | -40 920 | 1 738 287 | |
| 2015-06-12 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -1 116 | 1 133 253 | -0,10 | 1,60 | -1 786 | 1 813 205 | |
| 2015-06-12 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -11 703 | 1 134 369 | -1,02 | 1,61 | -18 842 | 1 826 334 | |
| 2015-06-12 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -3 454 | 1 146 072 | -0,30 | 1,60 | -5 526 | 1 833 715 | |
| 2015-06-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -13 280 | 1 149 526 | -1,14 | 1,60 | -21 248 | 1 839 242 | |
| 2015-06-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -38 120 | 1 162 806 | -3,17 | 1,60 | -60 992 | 1 860 490 | |
| 2015-06-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -55 476 | 1 200 926 | -4,42 | 1,69 | -93 754 | 2 029 565 | |
| 2015-06-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 10 000 | 46 810 | 27,17 | ||||
| 2015-05-18 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 13 500 | 13 500 | |||||
| 2015-05-18 |
|
4 | ECYT |
ENDOCYTE INC
Common Stock |
A - Award | 2 250 | 170 999 | 1,33 | ||||
| 2014-12-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -7 951 | 36 810 | -17,76 | 1,51 | -12 006 | 55 583 | |
| 2014-12-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -600 | 44 761 | -1,32 | 1,50 | -900 | 67 142 | |
| 2014-12-04 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -5 809 | 45 361 | -11,35 | 1,58 | -9 178 | 71 670 | |
| 2014-12-04 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -10 000 | 51 170 | -16,35 | 1,60 | -16 000 | 81 872 | |
| 2014-06-11 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 10 000 | 61 170 | 19,54 | ||||
| 2014-05-19 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 14 000 | 14 000 | |||||
| 2014-03-17 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -3 576 | 51 170 | -6,53 | 4,28 | -15 305 | 219 008 | |
| 2014-03-17 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -20 726 | 54 746 | -27,46 | 4,20 | -87 049 | 229 933 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -2 849 | 98 253 | -2,82 | 0,14 | -399 | 13 755 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -9 | 304 | -2,88 | 0,14 | -1 | 43 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -229 | 7 919 | -2,81 | 0,14 | -32 | 1 109 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -273 | 9 434 | -2,81 | 0,14 | -38 | 1 321 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -38 256 | 1 323 537 | -2,81 | 0,14 | -5 356 | 185 295 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -2 | 77 | -2,53 | 0,14 | -0 | 11 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 070 | 37 030 | -2,81 | 0,14 | -150 | 5 184 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -299 | 10 346 | -2,81 | 0,14 | -42 | 1 448 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -322 | 11 148 | -2,81 | 0,14 | -45 | 1 561 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 827 | 63 203 | -2,81 | 0,14 | -256 | 8 848 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 436 | 49 671 | -2,81 | 0,14 | -201 | 6 954 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -605 | 20 932 | -2,81 | 0,14 | -85 | 2 930 | |
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -12 502 | 0 | -100,00 | 0,14 | -1 750 | ||
| 2013-11-22 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -16 080 | 0 | -100,00 | 0,10 | -1 608 | ||
| 2013-11-20 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -20 900 | 16 080 | -56,52 | 0,22 | -4 598 | 3 538 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (rights to buy) |
S - Sale | -9 702 | 36 980 | -20,78 | 0,20 | -1 940 | 7 396 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -3 307 | 101 102 | -3,17 | 0,25 | -827 | 25 276 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -9 | 313 | -2,80 | 0,25 | -2 | 78 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -247 | 8 148 | -2,94 | 0,25 | -62 | 2 037 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -295 | 9 707 | -2,95 | 0,25 | -74 | 2 427 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -41 332 | 1 361 793 | -2,95 | 0,25 | -10 333 | 340 448 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -2 | 79 | -2,47 | 0,25 | -0 | 20 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 156 | 38 100 | -2,94 | 0,25 | -289 | 9 525 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -323 | 10 645 | -2,94 | 0,25 | -81 | 2 661 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -348 | 11 470 | -2,94 | 0,25 | -87 | 2 868 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 975 | 65 030 | -2,95 | 0,25 | -494 | 16 258 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 551 | 51 107 | -2,95 | 0,25 | -388 | 12 777 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -654 | 21 537 | -2,95 | 0,25 | -164 | 5 384 | |
| 2013-11-18 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 417 | 46 682 | -2,95 | 0,25 | -354 | 11 670 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 315 | 104 409 | -1,24 | 0,28 | -368 | 29 235 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -4 | 322 | -1,23 | 0,28 | -1 | 90 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -98 | 8 395 | -1,15 | 0,28 | -27 | 2 351 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -117 | 10 002 | -1,16 | 0,28 | -33 | 2 801 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -16 440 | 1 403 125 | -1,16 | 0,28 | -4 603 | 392 875 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -1 | 81 | -1,22 | 0,28 | -0 | 23 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -460 | 39 256 | -1,16 | 0,28 | -129 | 10 992 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -129 | 10 968 | -1,16 | 0,28 | -36 | 3 071 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -138 | 11 818 | -1,15 | 0,28 | -39 | 3 309 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -785 | 67 005 | -1,16 | 0,28 | -220 | 18 761 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -617 | 52 658 | -1,16 | 0,28 | -173 | 14 744 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -260 | 22 191 | -1,16 | 0,28 | -73 | 6 213 | |
| 2013-11-15 |
|
4 | STXS |
Stereotaxis, Inc.
Subscription Rights (right to buy) |
S - Sale | -563 | 48 099 | -1,16 | 0,28 | -158 | 13 468 | |
| 2013-08-27 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -2 000 | 0 | -100,00 | 3,67 | -7 340 | ||
| 2013-08-27 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -400 | 75 472 | -0,53 | 3,68 | -1 472 | 277 737 | |
| 2013-08-27 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -12 200 | 75 872 | -13,85 | 3,67 | -44 774 | 278 450 | |
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -26 506 | 0 | -100,00 | ||||
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -624 113 | 0 | -100,00 | ||||
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -13 950 | 40 673 | -25,54 | 6,39 | -89 140 | 259 900 | |
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 26 506 | 54 623 | 94,27 | 3,36 | 89 060 | 183 533 | |
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -328 475 | 1 256 402 | -20,73 | 6,39 | -2 098 955 | 8 028 409 | |
| 2013-08-15 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 624 113 | 1 584 877 | 64,96 | 3,36 | 2 097 020 | 5 325 187 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -2 900 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -566 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -3 455 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -675 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -75 759 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -149 849 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
M - Exercise | -29 248 | 0 | -100,00 | ||||
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -962 | 5 335 | -15,28 | 10,13 | -9 745 | 54 044 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 2 900 | 6 297 | 85,37 | 3,36 | 9 744 | 21 158 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -229 | 3 397 | -6,32 | 10,13 | -2 320 | 34 412 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 566 | 3 626 | 18,50 | 4,10 | 2 321 | 14 867 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -1 146 | 6 358 | -15,27 | 10,13 | -11 609 | 64 407 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 3 455 | 7 504 | 85,33 | 3,36 | 11 609 | 25 213 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -273 | 4 049 | -6,32 | 10,13 | -2 765 | 41 016 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 675 | 4 322 | 18,51 | 4,10 | 2 768 | 17 720 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -14 808 | 960 764 | -1,52 | 10,13 | -150 005 | 9 732 539 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 75 759 | 975 572 | 8,42 | 1,98 | 150 003 | 1 931 633 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -49 718 | 899 813 | -5,24 | 10,13 | -503 643 | 9 115 106 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 149 849 | 949 531 | 18,74 | 3,36 | 503 493 | 3 190 424 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
F - Taxes | -11 838 | 799 682 | -1,46 | 10,13 | -119 919 | 8 100 779 | |
| 2013-08-12 |
|
4/A | STXS |
Stereotaxis, Inc.
Common Stock |
M - Exercise | 29 248 | 811 520 | 3,74 | 4,10 | 119 917 | 3 327 232 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -2 900 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -566 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -3 455 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -675 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -75 759 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -149 849 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
X - Other | -29 248 | 0 | -100,00 | ||||
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -962 | 5 335 | -15,28 | 10,13 | -9 745 | 54 044 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 2 900 | 6 297 | 85,37 | 3,36 | 9 744 | 21 158 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -229 | 3 397 | -6,32 | 10,13 | -2 320 | 34 412 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 566 | 3 626 | 18,50 | 4,10 | 2 321 | 14 867 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -1 146 | 6 358 | -15,27 | 10,13 | -11 609 | 64 407 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 3 455 | 7 504 | 85,33 | 3,36 | 11 609 | 25 213 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -273 | 4 049 | -6,32 | 10,13 | -2 765 | 41 016 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 675 | 4 322 | 18,51 | 4,10 | 2 768 | 17 720 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -14 808 | 960 764 | -1,52 | 10,13 | -150 005 | 9 732 539 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 75 759 | 975 572 | 8,42 | 1,98 | 150 003 | 1 931 633 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -49 718 | 899 813 | -5,24 | 10,13 | -503 643 | 9 115 106 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 149 849 | 949 531 | 18,74 | 3,36 | 503 493 | 3 190 424 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
S - Sale | -11 838 | 799 682 | -1,46 | 10,13 | -119 919 | 8 100 779 | |
| 2013-08-09 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
X - Other | 29 248 | 811 520 | 3,74 | 4,10 | 119 917 | 3 327 232 | |
| 2013-08-02 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 32 258 | 32 258 | |||||
| 2013-08-02 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 9 542 | 9 542 | |||||
| 2013-06-25 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -5 900 | 0 | -100,00 | 28,70 | -169 330 | |
| 2013-06-25 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -2 828 | 5 900 | -32,40 | 28,49 | -80 570 | 168 091 |
| 2013-06-25 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -36 374 | 8 728 | -80,65 | 29,22 | -1 062 848 | 255 032 |
| 2013-06-25 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -2 222 | 0 | -100,00 | 28,49 | -63 305 | |
| 2013-06-25 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -28 576 | 2 222 | -92,79 | 29,22 | -834 991 | 64 927 |
| 2013-06-21 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 14 000 | 14 000 | |||||
| 2013-06-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -66 100 | 30 798 | -68,22 | 28,93 | -1 912 273 | 890 986 |
| 2013-06-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -48 400 | 96 898 | -33,31 | 29,76 | -1 440 384 | 2 883 684 |
| 2013-06-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -29 600 | 145 298 | -16,92 | 29,48 | -872 608 | 4 283 385 |
| 2013-06-14 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Stock Option (Right to Buy) |
A - Award | 7 000 | 7 000 | |||||
| 2013-06-07 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | 7 433 | 70 399 | 11,80 | ||||
| 2013-06-07 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | -241 185 | 174 898 | -57,97 | ||||
| 2013-06-07 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | -316 660 | 45 102 | -87,53 | ||||
| 2013-06-07 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 12 000 | 88 072 | 15,77 | ||||
| 2013-04-15 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
G - Gift | -5 000 | 62 966 | -7,36 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -348 951 | 559 453 | -38,41 | 27,86 | -9 721 775 | 15 586 361 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -20 069 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -843 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -708 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -20 220 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -17 839 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -750 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -629 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock Warrants (right to buy) |
X - Other | -17 973 | 0 | -100,00 | ||||
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -10 407 | 1 361 762 | -0,76 | 25,92 | -269 749 | 35 296 871 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -438 | 57 973 | -0,75 | 25,92 | -11 353 | 1 502 660 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -368 | 48 657 | -0,75 | 25,92 | -9 539 | 1 261 189 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -10 485 | 908 404 | -1,14 | 25,92 | -271 771 | 23 545 832 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 20 069 | 1 372 169 | 1,48 | 13,44 | 269 727 | 18 441 951 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 843 | 58 411 | 1,46 | 13,44 | 11 330 | 785 044 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 708 | 49 025 | 1,47 | 13,44 | 9 516 | 658 896 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 20 220 | 918 889 | 2,25 | 13,44 | 271 757 | 12 349 868 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1 852 | 1 352 100 | -0,14 | 25,92 | -48 004 | 35 046 432 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -78 | 57 568 | -0,14 | 25,92 | -2 022 | 1 492 163 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -66 | 48 317 | -0,14 | 25,92 | -1 711 | 1 252 377 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1 866 | 898 669 | -0,21 | 25,92 | -48 367 | 23 293 500 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 17 839 | 1 353 952 | 1,34 | 2,69 | 47 987 | 3 642 131 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 750 | 57 646 | 1,32 | 2,69 | 2 018 | 155 068 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 629 | 48 383 | 1,32 | 2,69 | 1 692 | 130 150 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
X - Other | 17 973 | 900 535 | 2,04 | 2,69 | 48 347 | 2 422 439 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -500 000 | 882 562 | -36,16 | 18,93 | -9 465 000 | 16 706 899 | |
| 2013-04-15 |
|
4/A | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | -98 596 | 0 | -100,00 | ||||
| 2013-04-02 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 75 758 | 75 758 | |||||
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -46 339 | 416 083 | -10,02 | 26,95 | -1 248 836 | 11 213 437 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -38 250 | 462 422 | -7,64 | 27,66 | -1 057 995 | 12 790 593 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -29 415 | 0 | -100,00 | 28,19 | -829 209 | |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -24 688 | 0 | -100,00 | 28,19 | -695 955 | |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -29 825 | 500 672 | -5,62 | 28,19 | -840 767 | 14 113 944 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -28 558 | 29 415 | -49,26 | 29,20 | -833 894 | 858 918 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -23 969 | 24 688 | -49,26 | 29,20 | -699 895 | 720 890 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -28 956 | 530 497 | -5,18 | 29,20 | -845 515 | 15 490 512 |
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | 25 133 | 67 966 | 58,68 | ||||
| 2013-03-20 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
J - Other | -200 000 | 0 | -100,00 | ||||
| 2012-12-04 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
P - Purchase | 24 360 | 76 072 | 47,11 | 1,53 | 37 271 | 116 390 | |
| 2012-08-24 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 11 471 | 45 564 | 33,65 | ||||
| 2012-06-07 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
A - Award | 7 000 | 7 000 | |||||
| 2012-06-04 |
|
4 | ECYT |
ENDOCYTE INC
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
P - Purchase | 265 062 | 265 062 | |||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
P - Purchase | 6 241 119 | 6 241 119 | |||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
P - Purchase | 265 062 | 281 178 | 1 644,71 | ||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
P - Purchase | 6 241 119 | 7 822 726 | 394,61 | ||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 34 553 | 34 553 | |||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 29 000 | 29 000 | |||||
| 2012-05-14 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 1 498 482 | 1 498 482 | |||||
| 2012-05-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 6 744 | 6 744 | |||||
| 2012-05-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 5 660 | 5 660 | |||||
| 2012-05-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 292 474 | 292 474 | |||||
| 2012-04-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 8 377 | 8 377 | |||||
| 2012-04-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 7 030 | 7 030 | |||||
| 2012-04-03 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock Warrant (right to buy) |
J - Other | 363 266 | 363 266 | |||||
| 2012-01-05 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 21 177 | 340 932 | 6,62 | ||||
| 2011-06-06 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Stock option (right to buy) |
A - Award | 15 692 | 15 692 | |||||
| 2011-05-27 |
|
4 | STXS |
Stereotaxis, Inc.
Stock Option (right to buy) |
A - Award | 28 000 | 28 000 | |||||
| 2011-05-27 |
|
4 | STXS |
Stereotaxis, Inc.
Common Stock |
A - Award | 7 200 | 287 786 | 2,57 | ||||
| 2011-02-04 | 3 | ECYT |
ENDOCYTE INC
Common Stock |
136 473 | ||||||||
| 2011-02-04 | 3 | ECYT |
ENDOCYTE INC
Common Stock |
33 429 | ||||||||
| 2011-02-04 | 3 | ECYT |
ENDOCYTE INC
Common Stock |
13 524 | ||||||||
| 2011-02-04 | 3 | ECYT |
ENDOCYTE INC
Common Stock |
83 769 | ||||||||
| 2011-02-04 | 3 | ECYT |
ENDOCYTE INC
Common Stock |
12 034 |
